<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781075</url>
  </required_header>
  <id_info>
    <org_study_id>2017.044 -TAP Block</org_study_id>
    <nct_id>NCT04781075</nct_id>
  </id_info>
  <brief_title>Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery</brief_title>
  <official_title>TAP (Transverse Abdominis Plane) Block With Exparel (Liposomal Bupivicaine) vs. Bupivicaine Post-op Pain Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single Blind, Randomized Controlled study to see if TAP Block with Exparel provides better&#xD;
      pain relief than TAP Block with bupivicaine. Differences in Pain Scale, Length of Stay, and&#xD;
      Total Narcotic use in the hospital will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects recruited into the study will undergo surgery as scheduled. During the procedure&#xD;
      they will receive a TAP Block with one of the pain medications. TAP Block in the experimental&#xD;
      arm will be performed with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of&#xD;
      bupivacaine diluted in 55 mL of normal saline. The control arm will have a TAP Block&#xD;
      performed with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline. These doses&#xD;
      are consistent with prior studies of TAP Block with liposomal bupivacaine. Subjects will be&#xD;
      monitored for pain as per standard of care and will be given pain medication as needed.&#xD;
&#xD;
      Subject Recruitment and Screening Patients will be recruited from the Ochsner Colorectal&#xD;
      Surgery Clinic at the time of a preoperative visit.&#xD;
&#xD;
      Study Procedures&#xD;
&#xD;
      Screening &amp; Baseline Visit After obtaining informed consent the subjects relevant medical and&#xD;
      surgical history will be documented. Demographics and vitals will be documented. Current use&#xD;
      of pain medication will be recorded. A physical exam will be performed.&#xD;
&#xD;
      Day of Surgery Routine vital signs will be obtained preoperatively. During the operation&#xD;
      subject will receive a TAP Block containing their randomized local injection mixture as&#xD;
      described above. Following surgery the subject will recover the PACU and pain medication will&#xD;
      be provided on demand. Initial postoperative vital signs and pain scores will be obtained at&#xD;
      this time.&#xD;
&#xD;
      Post-Operative Course Postoperatively subject will have regularly scheduled vital signs and&#xD;
      pain scores obtained, and recorded for study use. Narcotic and non-narcotic pain medication&#xD;
      will be provided on demand; dosages will be recorded for study use. Subjects will be followed&#xD;
      until they are discharged at which time study participation will be complete.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scale</measure>
    <time_frame>daily through study completion (up to 30 days)</time_frame>
    <description>Daily Pain Scale using Wong-baker FACES Pain Rating Scale 0 (no pain) - 10 (worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>daily through study completion (up to 30 days)</time_frame>
    <description>Duration of hospitalization post-operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic use</measure>
    <time_frame>daily through study completion (up to 30 days)</time_frame>
    <description>Total amount of narcotic used for pain control postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>TAP Block with Exparel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAP Block with 20 mL (266mg) of liposomal bupivacaine with 25 mL (5 mg/mL) of bupivacaine diluted in 55 mL of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAP Block with bupivicaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAP Block with 30 mL (5mg/mL) of bupivacaine diluted in 70 mL of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain Scale</intervention_name>
    <description>Maximum Daily Pain Scale will be recorded daily until discharge (typically under 7 days)</description>
    <arm_group_label>TAP Block with Exparel</arm_group_label>
    <arm_group_label>TAP Block with bupivicaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel Injectable Product</intervention_name>
    <description>Given at the beginning of the surgery for post-operative pain management</description>
    <arm_group_label>TAP Block with Exparel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Injection</intervention_name>
    <description>Given at the beginning of the surgery for post-operative pain management</description>
    <arm_group_label>TAP Block with bupivicaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 18-75 years undergoing planned laparoscopic colon or rectal resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 or older than 75 years old&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Patients who have taken steroids or other immunomodulators within the last 6 months&#xD;
&#xD;
          4. Patients on home narcotics&#xD;
&#xD;
          5. Patients allergic to Exparel or bupivacaine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Whitlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ochsner</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

